EUVIMEDEUVIMED entdecken
Leitlinie

Impact of the 2025 ASE Guidelines on the Classification of LV Diastolic Dysfunction in the Community: A Project Baseline Health Study

Nancy Herrera-Leaño iD, Bettia Celestin iD, Everton J Santana iD, Ryan Sandoval, Gracia Fahed iD, Patrick Khoury iD, Jack W O'Sullivan iD, Tatiana Kuznetsova iD, Nicholas Cauwenberghs iD, Kenneth W Mahaffey iD, Pamela S Douglas iD, Melissa M Daubert iD und 1 weitere

Circulation: Cardiovascular Imaging · 2026

DOI: 10.1161/circimaging.125.019402 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Circulation: Cardiovascular Imaging, 2026. Verfasst von Nancy Herrera-Leaño und 12 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cardiovascular Institute, Stanford University School of Medicine, CA (N.H.-L., B.C., P.K., F.H.). Hauptthemen laut MEDLINE: Ventricular Dysfunction, Left, Practice Guidelines as Topic, Ventricular Function, Left, Echocardiography. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The 2016 American Society of Echocardiography (ASE) guidelines for left ventricular diastolic dysfunction (LVDD) classification resulted in a significant proportion of indeterminate classifications and grades. To address these limitations and incorporate new evidence, the ASE updated its recommendations in 2025. The impact of these revisions in community cohorts remains unclear. METHODS: We studied 1953 Project Baseline Health Study participants who underwent comprehensive transthoracic echocardiography. LVDD was classified using the 2016 and 2025 ASE recommendations. For the 2025 recommendations, fixed and age-specific thresholds were evaluated separately. We compared LVDD prevalence, reclassification patterns, associations with cardiovascular risk factors, and prognostic value for major adverse cardiovascular events over a median follow-up of 4.3 years. RESULTS: Median patient age was 50.6 years (Q1–Q3: 36.3–64.2); 56.3% of patients were female, 35.3% had hypertension, and 14.2% had diabetes. The prevalence of LVDD was higher with the 2025 recommendations than with the 2016 algorithm: fixed criteria 308 (15.8%), age-specific criteria 220 (11.3%) versus ASE 2016 154 (8.0%). Among 119 (6.1%) participants classified as indeterminate by the 2016 algorithm, the 2025 recommendations reclassified 51.2% as no LVDD and 31.8% as Grade 2 LVDD. Participants reclassified as no LVDD had event-free survival that was not statistically different from those without LVDD ( P =0.26), whereas those reclassified as Grade 2 had higher event rates (12.5% versus 3.8%; P =0.02). Major adverse cardiovascular events occurred in 98 (5.0%) participants over the follow-up period. LVDD by all classification approaches was independently associated with major adverse cardiovascular events after adjustment for baseline risk factors. CONCLUSIONS: The 2025 ASE recommendations identified more participants with LVDD than the 2016 algorithm without indeterminate classification or grading. LVDD by the 2025 classification was significantly associated with major adverse cardiovascular events, supporting the clinical relevance of the revised framework.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ventricular Dysfunction, LeftPractice Guidelines as TopicVentricular Function, LeftEchocardiographyHumansFemaleMiddle AgedMaleAdultPrevalenceRisk FactorsUnited StatesPredictive Value of TestsDiastolePrognosisProspective StudiesRisk AssessmentTime Factors

Stichwörter der Autor:innen

age factorsclinical relevancehumansrisk factors

Autor:innen und Institutionen

  • Stanford Cardiovascular Institute, Stanford University School of Medicine, CA (N.H.-L., B.C., P.K., F.H.).
  • Division of Cardiovascular Medicine, Department of Medicine (B.C., R.S., F.H.), Stanford University, CA.
  • Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (E.J.S., T.K., N.C.).
  • Department of Internal Medicine, Yale School of Medicine and Yale New Haven Hospital, CT (G.F.).
  • Stanford School of Medicine (J.W.O.S), Stanford University, CA.
  • Stanford Center for Clinical Research, Department of Medicine, Stanford School of Medicine, CA (K.W.M.).

ORCID-Profile: Nancy Herrera-Leaño, Bettia Celestin, Everton J Santana, Gracia Fahed, Patrick Khoury, Jack W O'Sullivan, Tatiana Kuznetsova, Nicholas Cauwenberghs, Kenneth W Mahaffey, Pamela S Douglas, Melissa M Daubert, Francois Haddad

Zitieren

APA

Herrera-Leaño, N., Celestin, B., Santana, E. J., Sandoval, R., Fahed, G., Khoury, P., O'Sullivan, J. W., Kuznetsova, T., Cauwenberghs, N., Mahaffey, K. W., Douglas, P. S., Daubert, M. M., & Haddad, F. (2026). Impact of the 2025 ASE Guidelines on the Classification of LV Diastolic Dysfunction in the Community: A Project Baseline Health Study. Circulation: Cardiovascular Imaging. https://doi.org/10.1161/circimaging.125.019402

Vancouver

Herrera-Leaño N, Celestin B, Santana EJ, Sandoval R, Fahed G, Khoury P, et al. Impact of the 2025 ASE Guidelines on the Classification of LV Diastolic Dysfunction in the Community: A Project Baseline Health Study. Circulation: Cardiovascular Imaging. 2026. doi:10.1161/circimaging.125.019402

BibTeX
@article{HerreraLeao2026,
  author = {Herrera-Leaño, Nancy and Celestin, Bettia and Santana, Everton J and Sandoval, Ryan and Fahed, Gracia and Khoury, Patrick and O'Sullivan, Jack W and Kuznetsova, Tatiana and Cauwenberghs, Nicholas and Mahaffey, Kenneth W and Douglas, Pamela S and Daubert, Melissa M and Haddad, Francois},
  title = {Impact of the 2025 ASE Guidelines on the Classification of LV Diastolic Dysfunction in the Community: A Project Baseline Health Study},
  journal = {Circulation: Cardiovascular Imaging},
  year = {2026},
  doi = {10.1161/circimaging.125.019402}
}
Kostenlos starten →